Detalhe da pesquisa
1.
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
J Am Acad Dermatol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554938
2.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
JAMA
; 328(11): 1073-1084, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125472
3.
Antihistamines in Psoriasis.
J Drugs Dermatol
; 20(8): 844-847, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397204
4.
Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.
Dermatol Ther
; 33(4): e13800, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32530083
5.
Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement.
J Drugs Dermatol
; 19(8): 698-701, 2020 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845593
6.
Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis
J Drugs Dermatol
; 18(8): 776-788, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424708
7.
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol
; 18(3): 297-299, 2019 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30909352
8.
Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report
J Drugs Dermatol
; 18(4): 394-396, 2019 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31017383
9.
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
J Drugs Dermatol
; 17(8): 855-861, 2018 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30124724
10.
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.
J Am Acad Dermatol
; 76(2): 290-298, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908543
11.
Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
J Am Acad Dermatol
; 75(3): 612-618.e6, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27061047
12.
From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
J Am Acad Dermatol
; 75(4): 798-805.e7, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27461230
13.
Absence of Koebnerization Following Ablative and Nonablative Laser Therapy in Patients With Plaque Psoriasis.
Dermatol Surg
; 42(4): 521-5, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26981721
14.
IL-4 and IL-13 Inhibition in Atopic Dermatitis.
J Drugs Dermatol
; 15(8): 925-9, 2016 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537991
15.
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
J Cutan Med Surg
; 20(3): 196-206, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26712930
16.
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
J Am Acad Dermatol
; 72(1): 115-22, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264239
17.
Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
J Drugs Dermatol
; 14(3): 244-53, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25738846
18.
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
J Am Acad Dermatol
; 68(5): 756-64, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23357569
19.
Therapeutic application of machine learning in psoriasis: A Prisma systematic review.
J Cosmet Dermatol
; 22(2): 378-382, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35621249
20.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
JAMA Dermatol
; 159(6): 613-620, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133856